Many people are surprised by the fact that most of the known centenarians, smoked, drank, lacked sleep,
did not exercise and did not care about their health at all, while their peers, carefully monitored their
health, lived significantly less (Churchill phenomenon).
Studies have shown that such long-livers had a much higher activity of certain genes: FOXO, KLOTHO, SIRT,
FGF, AMPK, etc.
Higher activity of these genes protects against senile dementia, sarcopenia (age-related muscle wasting),
various oncological diseases, atherosclerosis, kidney failure, diabetes, and other age-related diseases that
eventually lead to death. Moreover, animals with artificially activated "longevity genes" lived 30-40%
longer than their wild-type counterparts. The role of these genes in aging has been proven by a plethora
of studies, but activation of these longevity genes is far from routine clinical practice.
But what about those who are not naturally gifted with such longevity genes? The solution is obvious: to
artificially add these genes to the body for the constant production of “youth hormones”.
Methods of gene delivery into a cell (vector delivery) is already widely tested: almost all COVID-19
vaccines, such as Sputnik, Pfizer, Moderna, AstraZeneca, etc., are based on this technology, and have
proven its effectiveness and safety literally on billions of patients worldwide. These vaccines carry the
genes for specific COVID-19 virus proteins that trigger the body's immune response.
The problem is that existing viral vectors aren’t safe because they can integrate in the genome and cause
potentially carcinogenic mutations. In addition, viral vectors are costly and difficult to manufacture.
The alternative technology, mRNA vectors, are essentially safer but very unstable and short-lived.
We, the Radical Life Extension Group (RLE Group), started developing our own vector three years ago and
are working to deliver the genes needed for health and longevity. We decided to create a non-viral vector
that is safer, easier and cheaper to produce and this is a crucial step towards a universal platform for
longevity genes delivery.
We are testing a genetic vector and its new cell delivery system based on silicon nanoparticles, the surface
of which was laser-treated to increase their penetration efficiency. We are now testing it on cell cultures,
and by early 2023 plan to proceed to testing on model animals - rats and guinea pigs (the work of new
genes in the body will be immediately visible by the level of the corresponding proteins in the blood).
Around the summer of 2023, we plan to make two vectors for pets - cats and dogs, and by the end of 2023
- a version for humans, and become the first testers and beneficiaries of this technology ourselves.
Thus, our biomedical engineering project, having very clear goals, will be a practical step to real longevity.
Developing a genetic vector is very high-tech and costly, so we call on interested people to help our
project. When the completed vector is obtained, tested, and ready for use, project participants will have
the primary opportunity 1) to use the product at a non-commercial price and 2) to participate in
subsequent commercialization.
For more information, see the project page: rle4.life/lg
RLE GROUP– Radical Life Extension Science Group rle4.life